Fully human recombinant antibodies against EphA2 from a multi-tumor patient immune library suitable for tumor-targeted therapy
Enhanced EphA2 expression is observed in a variety of epithelial-derived malignancies and is an important target for anti-tumor therapy. Currently, Therapeutic monoclonal antibodies against immune checkpoints have shown good efficacy for tumor treatment. In this study, we constructed an immune singl...
Guardado en:
Autores principales: | Yaqi Yang, Siji Nian, Lin Li, Xue Wen, Qin Liu, Bo Zhang, Yu Lan, Qing Yuan, Yingchun Ye |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Taylor & Francis Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/daf5e0fc23c045b3a0e3d757cde90cac |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase
por: Kanasap Kaewchim, et al.
Publicado: (2021) -
Homocysteine Impairs Endothelial Cell Barrier Function and Angiogenic Potential via the Progranulin/EphA2 Pathway
por: Dan Tian, et al.
Publicado: (2021) -
EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewing’s Sarcoma and Chondrosarcoma
por: Giorgia Giordano, et al.
Publicado: (2021) -
Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA
por: Zang X, et al.
Publicado: (2016) -
Overground Walking in a Fully Immersive Virtual Reality: A Comprehensive Study on the Effects on Full-Body Walking Biomechanics
por: Brian Horsak , et al.
Publicado: (2021)